Lusvertikimab posts strong phase II ulcerative colitis results, advancing
Lusvertikimab, an anti-IL-7 receptor antibody, reported robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic and histological endpoints. Development is advancing into pouchitis trials.
Lusvertikimab, an anti-IL-7 receptor antibody, showed robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvement across clinical, endoscopic and histological endpoints. The drug’s mechanism and biomarker-driven results support ongoing development…